Analysis of the polycythemia vera onset mechanism by investigating STAT5-target genes

• Project/Area Number: 23790096
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Biological pharmacy
• Research Institution: Keio University
• Principal Investigator: TAGO Megumi 慶應義塾大学, 薬学部, 講師 (30445192)
• Project Period (FY): 2011 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
• Keywords: JAK2 / V617F 点変異 / 真性赤血球増加症 / STAT5 / c-Myc / ODC / Aurka / 慢性骨髄増殖性腫瘍 / JAK2V617F変異体 / シグナル伝達

Research Abstract

A point mutant of a tyrosine kinase JAK2 (V617F), which is a cause gene of polycythemia vera, induces cell proliferation and tumorigenesis through activation of a transcription factor STAT5. In this study , we found that a transcription factor

Research Products

• [Journal Article] Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasmassociated JAK2 V617F mutant (2013)
  • Author(s): Funakoshi-Tago M, Sumi K, Kasahara T, Tago K
  • Journal Title: PLoS One Volume: 8(1)
  • Peer Reviewed
• [Journal Article] Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasmassociated Janus kinase 2 (JAK2) V617F mutant (2013)
  • Author(s): Funakoshi-Tago M
  • Journal Title: Yakugaku Zasshi Volume: 132(11) Pages: 1267-1272
  • Peer Reviewed
• [Journal Article] Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant. (2013)
  • Author(s): Funakoshi-Tago M, Sumi K, Kasahara T, Tago K.
  • Journal Title: PLoS One. Volume: 8 (1) Issue: 1 Pages: e52844-e52844
  • DOI: 10.1371/journal.pone.0052844
  • Peer Reviewed
• [Journal Article] Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway. (2012)
  • Author(s): Funakoshi-Tago M, Nagata T, Tago K, Tsukada M, Tanaka K, Nakamura S, Mashino T, Kasahara T.
  • Journal Title: Cell Signal. Volume: 24 (11) Issue: 11 Pages: 2024-2034
  • DOI: 10.1016/j.cellsig.2012.06.014
  • Peer Reviewed
• [Journal Article] Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant (2012)
  • Author(s): Funakoshi-Tago M
  • Journal Title: Yakugaku Zasshi. Volume: 132(11) Pages: 1267-1272
  • Peer Reviewed
• [Journal Article] Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway. (2012)
  • Author(s): Funakoshi-Tago M
  • Journal Title: 10.1016/j.cellsig. Volume: 24(11): Pages: 2024-2034
  • Peer Reviewed
• [Journal Article] Knockdown of proteolipid protein 2 or focal adhesion kinase with an artificial microRNA reduces growth and metastasis of B16BL6 melanoma cells. (2012)
  • Author(s): Ozawa H
  • Journal Title: Oncol Lett. Volume: 3(1) Pages: 19-24
  • Peer Reviewed
• [Journal Article] Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway (2011)
  • Author(s): Funakoshi-Tago M
  • Journal Title: Yakugaku Zasshi Volume: 131(8) Pages: 1183-1187
  • Peer Reviewed
• [Journal Article] Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells (2011)
  • Author(s): Sumi K, Tago K, Kasahara T, Funakoshi-Tago M.
  • Journal Title: FEBS Lett. Volume: 585(12) Issue: 12 Pages: 1884-1890
  • DOI: 10.1016/j.febslet.2011.04.068
  • Peer Reviewed
• [Journal Article] Anti-inflammatory activity of structurally related flavonoids, Apigenin, Luteolin and Fisetin (2011)
  • Author(s): Funakoshi-Tago M., et al
  • Journal Title: Int.Immunopharmacol. Volume: 11 Issue: 9 Pages: 1150-1159
  • DOI: 10.1016/j.intimp.2011.03.012
  • Peer Reviewed
• [Journal Article] Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation (2011)
  • Author(s): Kamishimoto J, et al
  • Journal Title: Cell.Signal. Volume: 23 Issue: 5 Pages: 849-856
  • DOI: 10.1016/j.cellsig.2011.01.009
  • Peer Reviewed
• [Journal Article] JAK2 is an important signal transducer in IL-33-induced NF-κB activation. (2011)
  • Author(s): Funakoshi-Tago, M., Tago, K., Sato, Y., Tominaga, S., and Kasahara, T.
  • Journal Title: Cell. Signal Volume: 23 Issue: 2 Pages: 363-370
  • DOI: 10.1016/j.cellsig.2010.10.006
  • Peer Reviewed
• [Presentation] Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells (2012)
  • Author(s): Megumi Funakoshi-Tago
  • Organizer: the 37th FEBS/22nd IUBMB Congress
  • Place of Presentation: Seville, Spain
  • Year and Date: 2012-07-30
• [Presentation] 慢性骨髄増殖性腫瘍の原因遺伝子JAK2V617F変異体の癌化シグナルの解析 (2012)
  • Author(s): 多胡めぐみ
  • Organizer: 日本薬学会第132年会(招待講演)
  • Place of Presentation: 札幌、北海道大学
• [Presentation] 慢性骨髄増殖性腫瘍の原因遺伝子 JAK2V617F 変異体の癌化シグナルの解析 (2011)
  • Author(s): 多胡めぐみ
  • Organizer: 日本薬学会
  • Year and Date: 2011-03-30
• [Presentation] JAK2変異体のシグナル伝達におけるPim1の役割の解析 (2011)
  • Author(s): 田中和之、多胡めぐみ、園田よし子、笠原忠
  • Organizer: 第84回日本生化学会大会
  • Place of Presentation: 京都、国立京都国際会館
• [Presentation] JAK2新規リン酸化部位の同定及び機能解析 (2011)
  • Author(s): 村上はるか、上四元純、多胡めぐみ、 笠原忠
  • Organizer: 第84回日本生化学会大会
  • Place of Presentation: 京都、国立京都国際会館
• [Presentation] JAK2変異体のシグナル伝達経路におけるPimの機能解析 (2011)
  • Author(s): 田中和之、多胡めぐみ、笠原忠
  • Organizer: 第55回日本薬学会関東支部大会
  • Place of Presentation: 千葉、東邦大学
• [Presentation] 慢性骨髄増殖性腫瘍由来JAK2変異体による抗がん剤耐性における FANCCの役割 (2011)
  • Author(s): 上田史仁、鷲見和也、多胡めぐみ、園田よし子、笠原忠
  • Organizer: 第55回日本薬学会関東支部大会
  • Place of Presentation: 千葉、東邦大学
• [Presentation] ピロリジニウム型フラーレン誘導体のJAK2変異体発現細胞のアポトーシス誘導効果 (2011)
  • Author(s): 塚田昌樹、豆田有香、多胡めぐみ、中村成夫、増野匡彦、笠原忠
  • Organizer: 第55回日本薬学会関東支部大会
  • Place of Presentation: 千葉、東邦大学
• [Presentation] 慢性骨髄増殖性腫瘍由来JAK2変異体のシグナル伝達におけるCISの機能解析 (2011)
  • Author(s): 森脇拓郎、岡本一飛、多胡めぐみ、笠原忠
  • Organizer: 第10回次世代を担う若手ファーマ・バイオフォーラム2011
  • Place of Presentation: 仙台、東北大学
• [Presentation] 慢性骨髄増殖性腫瘍由来JAK2変異体のシグナル伝達経路におけるc- Mycの役割 (2011)
  • Author(s): 庄司貴一、鷲見和也、多胡めぐみ、笠原忠
  • Organizer: 第12回Pharmaco-Hematologyシンポジウム
  • Place of Presentation: 富山、富山国際会議場
• [Presentation] フラーレン誘導体を用いた慢性骨髄増殖性腫瘍の治療法の開発 (2011)
  • Author(s): 田中和之、長田 達明、多胡 めぐみ、中村 成夫、増野 匡彦、笠原 忠
  • Organizer: 第12回Pharmaco-Hematologyシンポジウム
  • Place of Presentation: 富山、富山国際会議場
• [Presentation] JAK2変異体の増殖シグナルにおけるSOCS3の抑制機構の解析
  • Author(s): 石原 亜季
  • Organizer: 第５６回日本薬学会関東支部大会
  • Place of Presentation: 東京
• [Presentation] JAK2変異体による生存シグナルにおけるHMGA1bの役割
  • Author(s): 高橋 里実
  • Organizer: 第５６回日本薬学会関東支部大会
  • Place of Presentation: 東京
• [Presentation] フラーレン誘導体によるJAK2変異体発現細胞のアポトーシス誘導効果
  • Author(s): 渡邊俊朗
  • Organizer: 第５６回日本薬学会関東支部大会
  • Place of Presentation: 東京
• [Presentation] 慢性骨髄増殖性腫瘍由来JAK2変異体のがん化シグナルにおけるc-Myc-ODC経路の役割
  • Author(s): 多胡 めぐみ
  • Organizer: 第85回日本生化学大会
  • Place of Presentation: 福岡
• [Presentation] Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells.
  • Author(s): 多胡 めぐみ
  • Organizer: 第35回日本分子生物学会年会
  • Place of Presentation: 福岡
• [Presentation] Oncogenic signaling pathway induced by myeloproliferative neoplasm-associated
  • Author(s): 多胡 めぐみ
  • Organizer: the 37th FEBS/22nd IUBMB Congress
  • Place of Presentation: Spain (Seville)
  • Invited